Search

Your search keyword '"Kallen K"' showing total 124 results
Start Over Author "Kallen K"
124 results on '"Kallen K"'

2. Using Robson's Ten‐Group Classification System for comparing caesarean section rates in Europe: an analysis of routine data from the Euro‐Peristat study

Author

Zeitlin, J., Durox, M., Macfarlane, A. J., Alexander, S., Heller, G., Loghi, M., Nijhuis, J., Sól Ólafsdóttir, H., Mierzejewska, E., Gissler, M., Blondel, B., Haidinger, G., Klimont, J., Vandervelpen, G., Zhang, W-H., Jordanova, E., Kolarova, R., Filipovic‐Grcic, B., Drausnik, Z., Rodin, U., Kyprianou, T., Scoutellas, V., Velebil, P., Mortensen, L., Sakkeus, L., Heino, A., Chantry, A., Deneux Tharaux, C., Lack, N., Antsaklis, A., Berbik, I., Bonham, S., Kearns, K., Sikora, I., Cuttini, M., Misins, J., Zile, I., Isakova, J., Billy, A., Couffignal, S., Lecomte, A., Weber, G., Gatt, M., Achterberg, P., Broeders, L., Hindori‐Mohangoo, A., Akerkar, R., Klungsøyr, K., Szamotulska, K., Barros, H., Horga, M., Tica, V., Cap, J., Tul, N., Verdenik, I., Bolumar, F., Jané, M., Alcaide, A. R., Vidal, M. J., Zurriaga, O., Kallen, K., Nyman, A., Berrut, S., Riggenbach, M., Rihs, T. A., Smith, L., Woods, R., Delnord, M., Hocquette, A., RS: GROW - R4 - Reproductive and Perinatal Medicine, MUMC+: MA Obstetrie Gynaecologie (3), Obstetrie & Gynaecologie, and Instituto de Saúde Pública da Universidade do Porto

Subjects
medicine.medical_specialty, ten-group classification system, Epidemiology, RJ, medicine.medical_treatment, Population, RT, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, RA0421, medicine, Humans, Caesarean section, Ten‐Group Classification System, education, perinatal health indicators, reproductive and urinary physiology, education.field_of_study, 030219 obstetrics & reproductive medicine, Cesarean Section, Singleton, business.industry, Obstetrics, Obstetrics and Gynecology, Gestational age, Original Articles, Corrigenda, Robson classification, Ten group classification system, Europe, Caesarean Birth, Data quality, health information systems, Female, Original Article, Caesarean birth, Observational study, RG, business, Live Birth
Abstract

Objective Robson's Ten Group Classification System (TGCS) creates clinically relevant sub‐groups for monitoring caesarean birth rates. This study assesses whether this classification can be derived from routine data in Europe and uses it to analyse national caesarean rates. Design Observational study using routine data. Setting Twenty‐seven EU member states plus Iceland, Norway, Switzerland and the UK. Population All births at ≥22 weeks of gestational age in 2015. Methods National statistical offices and medical birth registers derived numbers of caesarean births in TGCS groups. Main outcome measures Overall caesarean rate, prevalence and caesarean rates in each of the TGCS groups. Results Of 31 countries, 18 were able to provide data on the TGCS groups, with UK data available only from Northern Ireland. Caesarean birth rates ranged from 16.1 to 56.9%. Countries providing TGCS data had lower caesarean rates than countries without data (25.8% versus 32.9%, P = 0.04). Countries with higher caesarean rates tended to have higher rates in all TGCS groups. Substantial heterogeneity was observed, however, especially for groups 5 (previous caesarean section), 6, 7 (nulliparous/multiparous breech) and 10 (singleton cephalic preterm). The differences in percentages of abnormal lies, group 9, illustrate potential misclassification arising from unstandardised definitions. Conclusions Although further validation of data quality is needed, using TGCS in Europe provides valuable comparator and baseline data for benchmarking and surveillance. Higher caesarean rates in countries unable to construct the TGCS suggest that effective routine information systems may be an indicator of a country's investment in implementing evidence‐based caesarean policies. Tweetable abstract Many European countries can provide Robson's Ten‐Group Classification to improve caesarean rate comparisons., Tweetable abstract Many European countries can provide Robson's Ten‐Group Classification to improve caesarean rate comparisons.

Published
2021
Full Text
View/download PDF

7. Trisomy 13 and 18—Prevalence and mortality—A multi‐registry population based analysis

Author

Goel, N, Morris, JK, Tucker, D, de Walle, HEK, Bakker, MK, Kancherla, V, Marengo, L, Canfield, MA, Kallen, K, Lelong, N, Camelo, JL, Stallings, EB, Jones, AM, Nance, A, Huynh, M-P, Martínez-Fernández, M-L, Sipek, A, Pierini, A, Nembhard, WN, Goetz, D, Rissmann, A, Groisman, B, Luna-Muñoz, L, Szabova, E, Lapchenko, S, Zarante, I, Hurtado-Villa, P, Martinez, LE, Tagliabue, G, Landau, D, Gatt, M, Dastgiri, S, and Morgan, M

Abstract

The aim of the study is to determine the prevalence, outcomes, and survival (among live births [LB]), in pregnancies diagnosed with trisomy 13 (T13) and 18 (T18), by congenital anomaly register and region. Twenty‐four population‐ and hospital‐based birth defects surveillance registers from 18 countries, contributed data on T13 and T18 between 1974 and 2014 using a common data‐reporting protocol. The mean total birth prevalence (i.e., LB, stillbirths, and elective termination of pregnancy for fetal anomalies [ETOPFA]) in the registers with ETOPFA (n = 15) for T13 was 1.68 (95% CI 1.3–2.06), and for T18 was 4.08 (95% CI 3.01–5.15), per 10,000 births. The prevalence varied among the various registers. The mean prevalence among LB in all registers for T13 was 0.55 (95%CI 0.38–0.72), and for T18 was 1.07 (95% CI 0.77–1.38), per 10,000 births. The median mortality in the first week of life was 48% for T13 and 42% for T18, across all registers, half of which occurred on the first day of life. Across 16 registers with complete 1‐year follow‐up, mortality in first year of life was 87% for T13 and 88% for T18. This study provides an international perspective on prevalence and mortality of T13 and T18. Overall outcomes and survival among LB were poor with about half of live born infants not surviving first week of life; nevertheless about 10% survived the first year of life. Prevalence and outcomes varied by country and termination policies. The study highlights the variation in screening, data collection, and reporting practices for these conditions.

Published
2019

8. Producing valid statistics when legislation, culture, and medical practices differ for births at or before the threshold of survival: Report of a European workshop

Author

Smith, L. K., Blondel, B., Zeitlin, J., Haidinger, G., Alexander, S., Kolarova, R., Rodin, U., Kyprianou, T., Velebil, P., Mortensen, L., Sakkeus, L., Gissler, M., Heller, G., Lack, N., Antsaklis, A., Berbik, I., Olafsdottir, H., Bonham, S., Cuttini, M., Misins, J., Isakova, J., Wagener, Y., Gatt, M., Nijhuis, J., Klungsoyr, K., Szamotulska, K., Barros, H., Horga, M., Cap, J., Tul, N., Bolumar, F., Gottvall, K., Kallen, K., Berrut, S., Riggenbach, M., Macfarlane, A. J., Zeitlin, J, Delnord, M., Durox, M., Hindori-Mohangoo, A., RS: GROW - R4 - Reproductive and Perinatal Medicine, MUMC+: MA Obstetrie Gynaecologie (3), Obstetrie & Gynaecologie, Department of Health Sciences [Leicester], University of Leicester, Equipe 1 : EPOPé - Épidémiologie Obstétricale, Périnatale et Pédiatrique (CRESS - U1153), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Euro-Peristat Scientific Committee: Gerald Haidinger, Sophie Alexander, Urelija Rodin, Theopisti Kyprianou, Petr Velebil, Laust Mortensen, Luule Sakkeus, Mika Gissler, Günther Heller, Nicholas Lack, Aris Antsaklis, István Berbik, Helga Sól Ólafsdóttir, Sheelagh Bonham, Marina Cuttini, Janis Misins, Jelena Isakova, Yolande Wagener, Miriam Gatt, Jan Nijhuis, Katarzyna Szamotulska, Henrique Barros, Mihai Horga, Jan Cap, Natasa Tul, Francisco Bolúmar, Karin Gottvall, Karin Källén, Sylvan Berrut, Mélanie Riggenbach, Alison Macfarlane, Marie Delnord, Mélanie Durox, Ashna Hindori-Mohangoo, Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and PHILIBERT, Marianne

Subjects
COUNTRIES, Quality management, Internationality, STILLBIRTHS, [SDV]Life Sciences [q-bio], Consensus Development Conferences as Topic, Perinatal Death, MEDLINE, Legislation, Gestational Age, Population health, DEFINITIONS, 03 medical and health sciences, 0302 clinical medicine, FETAL-DEATH, Environmental health, Medicine, Humans, RATES, ComputingMilieux_MISCELLANEOUS, Perinatal Mortality, Analysis of Variance, 030219 obstetrics & reproductive medicine, business.industry, Mortality rate, International comparisons, PRETERM BIRTHS, Infant, Newborn, Obstetrics and Gynecology, Gestational age, Public Reporting of Healthcare Data, Stillbirth, Quality Improvement, 3. Good health, [SDV] Life Sciences [q-bio], Europe, Vital Statistics, Perinatal Care, Commentary, Gestation, RG, business
Abstract

Perinatal mortality is a major population health indicatorconveying important signals about the state of maternitycare and measures of the current and future health ofmothers and newborns. International comparisons are usedto encourage countries to improve their perinatal healthand health systems. However, extensive evidence highlightsmethodological challenges to ensuring valid and robustcomparisons, as a lack of standardised criteria can lead tobias and inappropriate inferences.One major issue is the wide international variation in the criteria for classification and registration of deaths as a stillbirth or neonatal death at the threshold of survival.Standard practice is to minimise this problem by using a gestational age cut-off of 24 or even 28 weeks for mortality rate calculations. However, this strategy excludes a significant number of stillbirths, at least one in five deaths before 24 weeks of gestation and over one in three deaths before 28 weeks.As the gestational age limit for initiation of neonatal care decreases, exclusion of these stillbirths limits the full evaluation ofcare provision and outcomes at early gestational ages. Fur-ther, it underestimates the burden of loss on parents’ men-tal and physical health.

Published
2019
Full Text
View/download PDF

10. Fetal hemoglobin in umbilical cord blood in preeclamptic and normotensive pregnancies: A cross-sectional comparative study

Author

Than, NG, Masoumi, Z, Familari, M, Kallen, K, Ranstam, J, Olofsson, P, Hansson, SR, Than, NG, Masoumi, Z, Familari, M, Kallen, K, Ranstam, J, Olofsson, P, and Hansson, SR

Abstract

Preeclampsia (PE) is associated with increased fetal hemoglobin (HbF) in the maternal circulation but its source is unknown. To investigate whether excessive HbF is produced in the placenta or the fetus, the concentration of HbF (cHbF) in the arterial and venous umbilical cord blood (UCB) was compared in 15825 normotensive and 444 PE pregnancies. The effect of fetal gender on cHbF was also evaluated in both groups. Arterial and venous UCB sampled immediately after birth at 36-42 weeks of gestation were analyzed for total Hb concentration (ctHb) (g/L) and HbF% using a Radiometer blood gas analyzer. Non-parametric tests were used for statistical comparison and P values < 0.05 were considered significant. Our results indicated higher cHbF in venous compared to arterial UCB in both normotensive (118.90 vs 117.30) and PE (126.75 vs 120.12) groups. In PE compared to normotensive pregnancies, a significant increase was observed in arterial and venous ctHb (171.00 vs 166.00 and 168.00 vs 163.00, respectively) while cHbF was only significantly increased in venous UCB (126.75 vs 118.90). The pattern was similar in both genders. These results indicate a substantial placental contribution to HbF levels in UCB, which increases in PE and is independent of fetal gender, suggesting the elevated cHbF evident in PE results from placental dysfunction.

Published
2017

11. Developmental problems in extremely preterm children with borderline intellectual functioning and free from neurosensory disabilities at 6.5 years in Sweden (the EXPRESS study)

Author

Serenius, Fredrik, Farooqi, Aijaz, Fellman, V., Hafstrom, M., Kallen, K., Lindberg, E., Marsal, K., Olhager, E., Stjernqvist, K., Stromberg, B., Aden, U., Serenius, Fredrik, Farooqi, Aijaz, Fellman, V., Hafstrom, M., Kallen, K., Lindberg, E., Marsal, K., Olhager, E., Stjernqvist, K., Stromberg, B., and Aden, U.

Published
2016
Full Text
View/download PDF

12. Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins

Author

Althoff, K, Müllberg, J, Aasland, D, Voltz, N, Kallen, K, Grötzinger, J, and Rose-John, S

Subjects
Binding Sites, Sequence Homology, Amino Acid, Hydrolysis, Recombinant Fusion Proteins, Molecular Sequence Data, Membrane Proteins, Cell Biology, Biochemistry, COS Cells, Animals, Point Mutation, Amino Acid Sequence, Phosphorylation, Molecular Biology, Research Article, Signal Transduction
Abstract

Although regulated ectodomain shedding affects a large panel of structurally and functionally unrelated proteins, little is known about the mechanisms controlling this process. Despite a lack of sequence similarities around cleavage sites, most proteins are shed in response to the stimulation of protein kinase C by phorbol esters. The signal-transducing receptor subunit gp130 is not a substrate of the regulated shedding machinery. We generated several chimaeric proteins of gp130 and the proteins tumour necrosis factor alpha (TNF-alpha), transforming growth factor alpha (TGF-alpha) and interleukin 6 receptor (IL-6R), which are known to be subject to shedding. By exchanging small peptide sequences of gp130 for cleavage-site peptides of TNF-alpha, TGF-alpha and IL-6R we showed that these short sequences conferred susceptibility to spontaneous and phorbol-ester-induced shedding of gp130. Importantly, these chimaeric gp130 proteins were functional, as shown by the phosphorylation of gp130 and the activation of signal transduction and activators of transcription 3 ('STAT3') on stimulation with cytokine. To investigate minimal requirements for shedding, truncated cleavage-site peptides of IL-6R were inserted into gp130. The resulting chimaeras were susceptible to shedding and showed the same cleavage pattern as observed in the chimaeras containing the complete IL-6R cleavage site. Surprisingly, we could also generate cleavable chimaeras by exchanging the juxtamembrane sequence of gp130 for the corresponding region of leukaemia inhibitory factor ('LIF') receptor, a protein that like gp130 is not subject to regulated or spontaneous shedding. Thus it seems that there is no minimal consensus shedding sequence. We speculate that structural changes allow the access of the protease to a membrane-proximal region, leading to shedding of the protein.

Published
2001
Full Text
View/download PDF

13. Abstract B072: Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with disease control after first-line chemotherapy or during therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: Updated clinical results and immune responses

Author

Hipp, M. M., primary, Sebastian, M., additional, Weiss, C., additional, Früh, M., additional, Pless, M., additional, Cathomas, R., additional, Hilbe, W., additional, Pall, G., additional, Wehler, T., additional, Alt, J., additional, Bischoff, H., additional, Geißler, M., additional, Griesinger, F., additional, Kollmeier, J., additional, Papachristofilou, A., additional, Doener, F., additional, Fotin-Mleczek, M., additional, Hong, H. S., additional, Kallen, K. J., additional, Klinkhardt, U., additional, Koch, S. D., additional, Niehus, E., additional, Scheel, B., additional, Schröder, A., additional, Seibel, T., additional, Gnad-Vogt, U., additional, and Zippelius, A., additional

Published
2016
Full Text
View/download PDF

14. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy

Author

Brodie, M. J, Perucca, E, Ryvlin, P, Ben Menachem, E, Meencke, H. J, Van Landegem, W, Ossemann, M, Sadzot, B, Van Paesschen, W, Van Zandijcke, M, Hovorka, J, Marusic, P, Pazdera, L, Rektor, I, Stolcova, E, Tislerova, D, Kalviainen, R, Korpelainen, J, Peltola, J, Ranua, J, Geraud, G, Hirsch, E, Josien, E, Vercueil, L, Vespignani, H, Jeschke Rohrich, B, Keidel, M, Mattern, W, Ochs, G, Schmitz, B, Schumann, G, Balogh, A, Clemens, B, Czopf, J, Halasz, P, Rajna, P, Vecsei, L, Baruzzi, A, Beghi, A. E, Canevini, M. P, De Feo, M. R, Lamberti, P, Marciani, M. G, Marrosu, F, Mazza, Salvatore, Monaco, F, Mutani, R, Regesta, G, Zaccara, G, Drozdowski, W, Fryze, W, Jedrzejczak, J, Nowaki, P, Selmaj, K, Stelmasiak, Z, Wajgt, A, Bryer, A, Coetzee, C, Gardiner, J, Haug, P, Isaacs, M, Kelbe, C, Modi, G, Opperman, D, Shah, N, Wolberg, S, Arbizu, T, Forcadas, I, Macin Eiras, J. L, Martinez, M, Marti Masso, J. F, Molins, A, Serratosa, J. M, Borre, B, Kallen, K, Kumlien, E, Lindberger, M, Palm, R, Carpay, J. A, Sanders, E. A. C. M, Van Leusden, J. A, Vecht, C, Roberts, R. C, Smith, P, and Tidswell, P.

Subjects
business.industry, levetiracetam, oxcarbazepine, Carbamazepine, medicine.disease, law.invention, Epilepsy, Settore MED/26 - NEUROLOGIA, Tolerability, Randomized controlled trial, law, Anesthesia, Clinical endpoint, Medicine, epilepsy, Neurology (clinical), Levetiracetam, business, Adverse effect, Oxcarbazepine, medicine.drug
Abstract

Objective: We report the results of a prospective study of the efficacy and tolerability of levetiracetam, a new antiepileptic drug with a unique mechanism of action, in comparison with controlled-release carbamazepine as first treatment in newly diagnosed epilepsy. Methods: Adults with ≥2 partial or generalized tonic–clonic seizures in the previous year were randomly assigned to levetiracetam (500 mg twice daily, n = 288) or controlled-release carbamazepine (200 mg twice daily, n = 291) in a multicenter, double-blind, noninferiority, parallel-group trial. If a seizure occurred within 26 weeks of stabilization, dosage was increased incrementally to a maximum of levetiracetam 1,500 mg twice daily or carbamazepine 600 mg twice daily. Patients achieving the primary endpoint (6-month seizure freedom) continued on treatment for a further 6-month maintenance period. Results: At per-protocol analysis, 73.0% (56.6%) of patients randomized to levetiracetam and 72.8% (58.5%) receiving controlled-release carbamazepine were seizure free at the last evaluated dose (adjusted absolute difference 0.2%, 95% CI −7.8% to 8.2%) for ≥6 months (1 year). Of all patients achieving 6-month (1-year) remission, 80.1% (86.0%) in the levetiracetam group and 85.4% (89.3%) in the carbamazepine group did so at the lowest dose level. Withdrawal rates for adverse events were 14.4% with levetiracetam and 19.2% with carbamazepine. Conclusions: Levetiracetam and controlled-release carbamazepine produced equivalent seizure freedom rates in newly diagnosed epilepsy at optimal dosing in a setting mimicking clinical practice. This trial has confirmed in a randomized, double-blind setting previously uncontrolled observations that most people with epilepsy will respond to their first-ever antiepileptic drug at low dosage.

Published
2007

15. The IL-6R α chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo

Author

Doganci, A., Eigenbrod, T., Krug, N., De Sanctis, G. T., Hausding, M., Erpenbeck, V. J., Haddad, e., Lehr, H. A., Schmitt, E., Bopp, T., Kallen, K. J., Herz, U., Schmitt, S., Luft, C., Hecht, O., Hohlfeld, J. M., Ito, H., Nishimoto, N., Yoshizaki, K., Kishimoto, T., Rose-John, S., Renz, H., Neurath, M. F., Galle, P. R., Finotto, S., and Publica

Subjects
Adult, Male, STAT3 Transcription Factor, Ovalbumin, Article, Antibodies, Mice, Th2 Cells, immune system diseases, Hypersensitivity, Animals, Humans, Receptors, Cytokine, Lung, Homeodomain Proteins, Inflammation, Mice, Knockout, Forkhead Transcription Factors, Receptors, Interleukin-2, General Medicine, Receptors, Interleukin-6, Asthma, Adult/Animals/Antibodies/administration & dosage/immunology/Asthma/Pathology/DNA-Binding Proteins/Female/Forkhead Transcription Factors/Homeodomain Proteins/genetics/Humans/Hypersensitivity/Inflammation/Lung/Male/Mice/Mice,Knockout/Ovalbumin/metabolism/Receptors,Cytokine/Receptors,Interleukin-2/Receptors,Interleukin-6/STAT3 Transcription Factor/Signal Transduction/drug effects/Th2 Cells/Trans-Activators, DNA-Binding Proteins, Trans-Activators, Female, Corrigendum, Signal Transduction
Abstract

The cytokine IL-6 acts via a specific receptor complex that consists of the membrane-bound IL-6 receptor (mIL-6R) or the soluble IL-6 receptor (sIL-6R) and glycoprotein 130 (gp130). In this study, we investigated the role of IL-6R components in asthma. We observed increased levels of sIL-6R in the airways of patients with allergic asthma as compared to those in controls. In addition, local blockade of the sIL-6R in a murine model of late-phase asthma after OVA sensitization by gp130-fraction constant led to suppression of Th2 cells in the lung. By contrast, blockade of mIL-6R induced local expansion of Foxp3-positive CD4+CD25+ Tregs with increased immunosuppressive capacities. CD4+CD25+ but not CD4+CD25- lung T cells selectively expressed the IL-6R alpha chain and showed IL-6-dependent STAT-3 phosphorylation. Finally, in an in vivo transfer model of asthma in immunodeficient Rag1 mice, CD4+CD25+ T cells isolated from anti-IL-6R antibody-treated mice exhibited marked immunosuppressive and antiinflammatory functions. IL-6 signaling therefore controls the balance between effector cells and Tregs in the lung by means of different receptor components. Furthermore, inhibition of IL-6 signaling emerges as a novel molecular approach for the treatment of allergic asthma.

Published
2005

16. The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo

Author

Doganci, A., Eigenbrod, T., Krug, N., Sanctis, G.T. de, Hausding, M., Erpenbeck, V.J., Haddad, E.-B., Schmitt, E., Bopp, T., Kallen, K.-J., Herz, U., Schmitt, S., Luft, C., Hecht, O., Hohlfeld, J.M., Ito, H., Nishimoto, N., Yoshizaki, K., Kishimoto, T., Rose-John, S., Renz, H., Neurath, M.F., Galle, P.R., Finotto, S., and Publica

Subjects
Inflammation, Mice, Th2 cell, homeodomain protein, receptor, cytokine, DNA binding proteins, Hypersensitivity, forkhead transcription factor, ovalbumin, trans-activator, Lungs, Signal transduction, Asthma
Abstract

The cytokine IL-6 acts via a specific receptor complex that consists of the membrane-bound IL-6 receptor (mIL-6R) or the soluble IL-6 receptor (sIL-6R) and glycoprotein 130 (gp130). In this study, we investigated the role of IL-6R components in asthma. We observed increased levels of sIL-6R in the airways of patients with allergic asthma as compared to those in controls. In addition, local blockade of the sIL-6R in a murine model of late-phase asthma after OVA sensitization by gp130-fraction constant led to suppression of Th2 cells in the lung. By contrast, blockade of mIL-6R induced local expansion of Foxp3-positive CD4+CD25+ Tregs with increased immunosuppressive capacities. CD4+CD25+ but not CD4+CD25- lung T cells selectively expressed the IL-6R alpha chain and showed IL-6-dependent STAT-3 phosphorylation. Finally, in an in vivo transfer model of asthma in immunodeficient Rag1 mice, CD4+CD25+ T cells isolated from anti-IL-6R antibody-treated mice exhibited marked immunosuppressive and antiinflammatory functions. IL-6 signaling therefore controls the balance between effector cells and Tregs in the lung by means of different receptor components. Furthermore, inhibition of IL-6 signaling emerges as a novel molecular approach for the treatment of allergic asthma.

Published
2005

17. Cancer in children and young adults born after assisted reproductive technology: a Nordic cohort study from the Committee of Nordic ART and Safety (CoNARTaS)

Author

Sundh, K. J., primary, Henningsen, A.-K. A., additional, Kallen, K., additional, Bergh, C., additional, Romundstad, L. B., additional, Gissler, M., additional, Pinborg, A., additional, Skjaerven, R., additional, Tiitinen, A., additional, Vassard, D., additional, Lannering, B., additional, and Wennerholm, U.-B., additional

Published
2014
Full Text
View/download PDF

18. Improving the efficacy of cancer immunotherapy

Author

Copier, J, Dalgleish, A G, Britten, C M, Finke, L H, Gaudernack, G, Gnjatic, S, Kallen, K, Kiessling, R, Schuessler-Lenz, M, Singh, H, Talmadge, J, Zwierzina, H, Håkansson, L, Copier, J, Dalgleish, A G, Britten, C M, Finke, L H, Gaudernack, G, Gnjatic, S, Kallen, K, Kiessling, R, Schuessler-Lenz, M, Singh, H, Talmadge, J, Zwierzina, H, and Håkansson, L

Abstract

A series of cancer vaccines have been evaluated in clinical trials with encouraging results, but the demonstration of clinical benefit in confirmatory studies has so far proven to be difficult. The development of cancer vaccines is hampered by a range of issues particular to this field of research. On 12th March 2008, the Biotherapy Development Association convened a workshop to discuss issues faced by scientists and clinicians involved in the development of cancer vaccines. This paper is a review of the field, based on discussions held at the BDA workshop, and describes biological barriers encountered in generating effective immune responses to tumours, methodological obstacles encountered in the improvement of immunological monitoring which aims to improve inter-laboratory and inter-trial comparisons, challenges in clinical trial design and problems posed by the lack of specific regulation for cancer vaccines and the impact on their development. Ultimately, a number of general solutions are posed: (1) better patient selection, (2) use of multi-modal treatments that affect several aspects of the immune system at once, (3) a requirement for the development of good biomarkers to stratify patients for selection prior to trial and as surrogates for clinical response and (4) harmonisation of SOPs for immunological monitoring of clinical trials.

Published
2009
Full Text
View/download PDF

19. HIGH ONE-YEAR SURVIVAL AFTER ACTIVE PERINATAL CARE : EXTREMELY PRETERM INFANTS IN SWEDEN (EXPRESS)

Author

Blennow, M, Ewald, U, Fritz, T, Fellman, V, Hellstrorm-Westas, L, Holmgren, P A, Holmstrom, G, Jeppsson, Annika, Kallen, K, Lagercrantz, H, Laurini, R, Lindberg, E, Lundqvist, A, Marsal, K, Nilstun, T, Norden-Lindeberg, S, Norman, M, Olhager, Elisabeth, Otterblad Olausson, P, Ostlund, I, Serenius, F, Simic, M, Sjors, G, Stigsson, L, Stjernqvist, K, Stromberg, B, Wennergren, M, Westgren, M, Blennow, M, Ewald, U, Fritz, T, Fellman, V, Hellstrorm-Westas, L, Holmgren, P A, Holmstrom, G, Jeppsson, Annika, Kallen, K, Lagercrantz, H, Laurini, R, Lindberg, E, Lundqvist, A, Marsal, K, Nilstun, T, Norden-Lindeberg, S, Norman, M, Olhager, Elisabeth, Otterblad Olausson, P, Ostlund, I, Serenius, F, Simic, M, Sjors, G, Stigsson, L, Stjernqvist, K, Stromberg, B, Wennergren, M, and Westgren, M

Abstract

n/a

Published
2009

20. Reference population for international comparisons and time trend surveillance of preterm delivery proportions in three countries

Author

Morken, N.H., Vogel, I., Kallen, K., Skjaerven, R., Langhoff-Roos, J., Kesmodel, U.S., Jacobsson, B., Morken, N.H., Vogel, I., Kallen, K., Skjaerven, R., Langhoff-Roos, J., Kesmodel, U.S., and Jacobsson, B.

Abstract

BACKGROUND: International comparison and time trend surveillance of preterm delivery rates is complex. New techniques that could facilitate interpretation of such rates are needed. METHODS: We studied all live births and stillbirths (>or= 28 weeks gestation) registered in the medical birth registers in Sweden, Denmark and Norway from 1995 through 2004. Gestational age was determined by best estimate. A reference population of pregnant women was designed using the following criteria: 1) maternal age 20-35, 2) primiparity, 3) spontaneously conceived pregnancy, 4) singleton pregnancy and 5) mother born in the respective country. National preterm delivery rate, preterm delivery rate in the reference population and rate of spontaneous preterm delivery in the reference population were calculated for each country. RESULTS: The total national preterm delivery rate (< 37 completed gestational weeks), increased in both Denmark (5.3% to 6.1%, p < 0.001) and Norway (6.0% to 6.4%, p = 0.006), but remained unchanged in Sweden, during 1995-2004. In Denmark, the preterm delivery rate in the reference population (5.3% to 6.3%, p < 0.001) and the spontaneous preterm delivery rate in the reference population (4.4% to 6.8%, p < 0.001) increased significantly. No similar increase was evident in Norway. In Sweden, rates in the reference population remained stable. CONCLUSION: Reference populations can facilitate overview and thereby explanations for changing preterm delivery rates. The model also permits comparisons over time. This model may in its simplicity prove to be a valuable supplement to assessments of national preterm delivery rates for public health surveillance Udgivelsesdato: 2008

Published
2008

21. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

Author

Ebers, GC, Rice, G, Lesaux, J, Paty, D, Oger, J, Li, DKB, Beall, S, Devonshire, V, Hashimoto, S, Hooge, J, Kastrukoff, L, Krieger, C, Mezei, M, Seland, P, Vorobeychi, G, Morrison, W, Nelson, J, Freedman, MS, Chrisie, S, Nelson, R, Rabinovitch, H, Freedman, C, Hartung, HP, Rieckmann, P, Archelos, J, Jung, S, Weilbach, F, Flachenecke, P, Sauer, J, Hommes, O, Jongen, P, Brouwer, S, McLeod, J, Pollard, J, Ng, R, Sandberg-Wollheim, M, Kallen, K, Nilsson, P, Ekberg, R, Lundgren, A, Jadback, G, Wikstrom, J, Multanen, J, Valjakka, M, Carton, H, Lissoir, F, Declerq, I, Vieren, M, Peeters, E, Dubois, B, Dekeersmaeker, E, Van Herle, A, Hughes, RAC, Sharrack, B, Soudain, S, Panelius, M, Eralinna, J, Soilu-Hanninen, M, Murto, S, Medaer, R, Broeckx, J, Vanroose, E, Bogaers, A, Blumhardt, LD, Edwards, S, Liu, C, Orpe, V, Barnes, D, Schwartz, M, Stoy, N, Harraghy, C, Bertelsmann, F, Uitdehaag, B, Nasseri, K, Chofflon, M, Roth, S, Kappos, L, Huber, S, Bellaiche, Y, Senn, C, King, J, Jubert, J, Whitten, S, Newsom-Davis, JM, Palace, J, Lee, M, Evangelou, N, Pinto, A, Cavey, A, Sindic, CJM, Monteyne, P, Verougstraete, D, Van Doorn, PA, Moll, W, Visser, L, Willems, M, Martina, I, Buljevac, D, Loman, L, Bates, D, Pandit, D, Irving, J, Rhodes, B, Riddehough, A, Zhao, GJ, Wang, X, Cheng, Y, Ammoury, N, Dupont, F, Galazka, A, Hyde, R, Olson, M, Pernin, MO, Abdul-Ahad, AK, Noseworthy, J, Borden, E, O'Brien, P, Wolinsky, J, and Grp, PRISMSS

Abstract

BACKGROUND: Previous trials of interferon beta in multiple sclerosis (MS) have shown efficacy, but the degree of clinical benefit remains uncertain, and the optimum dose is not known. We undertook a double-blind, placebo-controlled study in relapsing/remitting MS to investigate the effects of subcutaneous interferon beta-1a. METHODS: 560 patients with Kurtzke expanded disability status scale (EDSS) scores of 0-5.0, from 22 centres in nine countries, were randomly assigned subcutaneous recombinant interferon beta-1a 22 microg (n=189), or 44 microg (n=184), or placebo (n=187) three times a week for 2 years. Neurological examinations were done every 3 months. All patients had MRI twice yearly and 205 had monthly scans in the first 9 months of treatment. Analysis was by intention to treat. FINDINGS: Clinical data on 533 (95%) patients were available at 2 years. The relapse rate was significantly lower at 1 and 2 years with both doses of interferon beta-1a than with placebo (mean number per patient 1.82 for 22 microg group, 1.73 for 44 microg group vs 2.56 for placebo group: risk reductions 27% [95% CI 14-39] and 33 [21-44]). Time to first relapse was prolonged by 3 and 5 months in the 22 microg and 44 microg groups respectively, and the proportion of relapse-free patients was significantly increased (p

Published
1998

24. Session 44: Long term outcome of ART

Author

Sullivan, E., primary, Hilder, L., additional, Wang, Y. A., additional, Sundh, K. J., additional, Bergh, C., additional, Henningsen, A. K. A., additional, Kallen, K., additional, Romundstad, L. B., additional, Pinborg, A., additional, Nyboe-Andersen, A., additional, Skjaerven, R., additional, Gissler, M., additional, Tiitinen, A., additional, Nygren, K. G., additional, Wennerholm, U. B., additional, Williams, C. L., additional, Bunch, K. J. K., additional, Stiller, C. A., additional, Murphy, M. F. G., additional, Wallce, W. H., additional, Davies, M., additional, Botting, B., additional, Sutcliffe, A. G., additional, Cesta, C. E., additional, Olsson, H., additional, Cnattingius, S., additional, Johansson, V., additional, Lichtenstein, P., additional, Iliadou, A. N., additional, Gameiro, S., additional, van den Belt-Dusebout, A. W., additional, Bleiker, E., additional, Braat, D., additional, van Leeuwen, F. E., additional, and Verhaak, C. M., additional

Published
2013
Full Text
View/download PDF

26. O11 Final analysis of a phase I/II study with CV9103: An intradermally administered prostate cancer vaccine based on self-adjuvanted mRNA (RNActive®)

Author

Kübler, H., primary, Maurer, T., additional, Stenzl, A., additional, Feyerabend, S., additional, Steiner, U., additional, Schostak, M., additional, Schultze-Seemann, W., additional, Vom Dorp, F., additional, Pilla, L., additional, Parmiani, G., additional, Hampel, C., additional, Wedel, S., additional, Trojan, L., additional, Hiller, K., additional, Sommerauer, M., additional, Jocham, D., additional, Birgit, B., additional, Reindl, M., additional, Lander, T., additional, Kallen, K., additional, Gnad-Vogt, U., additional, and Kurt, K., additional

Published
2012
Full Text
View/download PDF

28. FEMALE (IN)FERTILITY

Author

Kanta Goswami, S., primary, Banerjee, S., additional, Saha, P., additional, Chakraborty, P., additional, Kabir, S. N., additional, Karimzadeh, M. A., additional, Mohammadian, F., additional, Mashayekhy, M., additional, Saldeen, P., additional, Kallen, K., additional, Karlstrom, P. O., additional, Rodrigues-Wallberg, K. A., additional, Salerno, A., additional, Nazzaro, A., additional, Di Iorio, L., additional, Marino, S., additional, Granato, C., additional, Landino, G., additional, Pastore, E., additional, Ghoshdastidar, B., additional, Chakraborty, C., additional, Ghoshdastidar, B. N., additional, Ghoshdastidar, S., additional, Partsinevelos, G. A., additional, Papamentzelopoulou, M., additional, Mavrogianni, D., additional, Marinopoulos, S., additional, Dinopoulou, V., additional, Theofanakis, C., additional, Anagnostou, E., additional, Loutradis, D., additional, Franz, C., additional, Nieuwland, R., additional, Montag, M., additional, Boing, A., additional, Rosner, S., additional, Germeyer, A., additional, Strowitzki, T., additional, Toth, B., additional, Mohamed, M., additional, Vlismas, A., additional, Sabatini, L., additional, Caragia, A., additional, Collins, B., additional, Leach, A., additional, Zosmer, A., additional, Al-Shawaf, T., additional, Beyhan, Z., additional, Fisch, J. D., additional, Danner, C., additional, Keskintepe, L., additional, Aydin, Y., additional, Ayca, P., additional, Oge, T., additional, Hassa, H., additional, Papanikolaou, E., additional, Pados, G., additional, Grimbizis, G., additional, Bili, H., additional, Karastefanou, K., additional, Fatemi, H., additional, Kyrou, D., additional, Humaidan, P., additional, Tarlatzis, B., additional, Gungor, F., additional, Karamustafaoglu, B., additional, Iyibozkurt, A. C., additional, Ozsurmeli, M., additional, Bastu, E., additional, Buyru, F., additional, Di Emidio, G., additional, Vitti, M., additional, Mancini, A., additional, Baldassarra, T., additional, D'Alessandro, A. M., additional, Polsinelli, F., additional, Tatone, C., additional, Leperlier, F., additional, Lammers, J., additional, Dessolle, L., additional, Lattes, S., additional, Barriere, P., additional, Freour, T., additional, Elodie, P., additional, Assou, S., additional, Van den Abbeel, E., additional, Arce, J. C., additional, Hamamah, S., additional, Dechaud, H., additional, Haouzi, D., additional, Tiplady, S., additional, Johnson, S., additional, Jones, G., additional, Ledger, W., additional, Eizadyar, N., additional, Ahmad Nia, S., additional, Seyed Mirzaie, M., additional, Azin, S. A., additional, Yazdani Safa, M., additional, Onaran, Y., additional, Iltemir Duvan, C., additional, Keskin, E., additional, Ayrim, A., additional, Kafali, H., additional, Kadioglu, N., additional, Guler, B., additional, Var, T., additional, Cicek, M. N., additional, Batioglu, A. S., additional, Lichtblau, I., additional, Olivennes, F., additional, de Mouzon, J., additional, Dumont, M., additional, Junca, A. M., additional, Cohen-Bacrie, M., additional, Hazout, A., additional, Belloc, S., additional, Cohen-Bacrie, P., additional, Allegra, A., additional, Marino, A., additional, Sammartano, F., additional, Coffaro, F., additional, Scaglione, P., additional, Gullo, S., additional, Volpes, A., additional, Prisant, N., additional, Saare, M., additional, Vaidla, K., additional, Salumets, A., additional, Peters, M., additional, Jindal, U. N., additional, Thakur, M., additional, Shvell, V., additional, Diamond, M. P., additional, Awonuga, A. O., additional, Veljkovic, M., additional, Macanovic, B., additional, Milacic, I., additional, Borogovac, D., additional, Arsic, B., additional, Pavlovic, D., additional, Lekic, D., additional, Bojovic Jovic, D., additional, Garalejic, E., additional, Jayaprakasan, K., additional, Eljabu, H., additional, Hopkisson, J., additional, Campbell, B., additional, Raine-Fenning, N., additional, Kop, P., additional, van Wely, M., additional, Mol, B. W., additional, Melker, A. A., additional, Janssens, P. M. W., additional, Nap, A., additional, Arends, B., additional, Roovers, J. P. W. R., additional, Ruis, H., additional, Repping, S., additional, van der Veen, F., additional, Mochtar, M. H., additional, Sargin, A., additional, Yilmaz, N., additional, Gulerman, C., additional, Guven, A., additional, Polat, B., additional, Ozel, M., additional, Bardakci, Y., additional, Vidal, C., additional, Giles, J., additional, Remohi, J., additional, Pellicer, A., additional, Garrido, N., additional, Javdani, M., additional, Fallahzadeh, H., additional, Davar, R., additional, Sheibani, H., additional, Leary, C., additional, Killick, S., additional, Sturmey, R. G., additional, Kim, S. G., additional, Lee, K. H., additional, Park, I. H., additional, Sun, H. G., additional, Lee, J. H., additional, Kim, Y. Y., additional, Choi, E. M., additional, Van Loendersloot, L. L., additional, Van Wely, M., additional, Bossuyt, P. M. M., additional, Van Der Veen, F., additional, Roychoudhury Sarkar, M., additional, Roy, D., additional, Sahu, R., additional, Bhattacharya, J., additional, Eguiluz Gutierrez- Barquin, I., additional, Sanchez Sanchez, V., additional, Torres Afonso, A., additional, Alvarez Sanchez, M., additional, De Leon Socorro, S., additional, Molina Cabrillana, J., additional, Seara Fernandez, S., additional, Garcia Hernandez, J. A., additional, Ozkan, Z. S., additional, Simsek, M., additional, Kumbak, B., additional, Atilgan, R., additional, Sapmaz, E., additional, Agirregoikoa, J. A., additional, DePablo, J. L., additional, Abanto, E., additional, Gonzalez, M., additional, Anarte, C., additional, Barrenetxea, G., additional, Aleyasin, A., additional, Mahdavi, A., additional, Agha Hosseini, M., additional, Safdarian, L., additional, Fallahi, P., additional, Bahmaee, F., additional, Sarikaya, E., additional, Segawa, T., additional, Teramoto, S., additional, Tsuchiyama, S., additional, Miyauchi, O., additional, Watanabe, Y., additional, Ohkubo, T., additional, Shozu, M., additional, Ishikawa, H., additional, Yelian, F., additional, Papaioannou, S., additional, Knowles, T., additional, Aslam, M., additional, Milnes, R., additional, Takashima, A., additional, Takeshita, N., additional, Kinoshita, T., additional, Chapman, M. G., additional, Kilani, S., additional, Dadras, N., additional, Parsanezhad, M. E., additional, Zolghadri, J., additional, Younesi, M., additional, Floehr, J., additional, Dietzel, E., additional, Wessling, J., additional, Neulen, J., additional, Rosing, B., additional, Tan, S., additional, Jahnen-Dechent, W., additional, Lee, K. S., additional, Joo, J. K., additional, Son, J. B., additional, Joo, B. S., additional, Risquez, F., additional, Confino, E., additional, Llavaneras, F., additional, Marval, I., additional, D'Ommar, G., additional, Gil, M., additional, Risquez, M., additional, Lozano, L., additional, Paublini, A., additional, Piras, M., additional, Risquez, A., additional, Prochazka, R., additional, Blaha, M., additional, Nemcova, L., additional, Weghofer, A., additional, Kim, A., additional, Barad, D. H., additional, Gleicher, N., additional, Kilic, Y., additional, Ergun, B., additional, Howard, B., additional, Weiss, H., additional, Doody, K., additional, Schafer, C., additional, Ensslen, S., additional, Denecke, B., additional, Veitinger, T., additional, Spehr, M., additional, Tropartz, T., additional, Tolba, R., additional, Egert, A., additional, Schorle, H., additional, Alanya, S., additional, and Yumru, H., additional

Published
2012
Full Text
View/download PDF

30. Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical trial.

Author

Sebastian, M., primary, von Boehmer, L., additional, Zippelius, A., additional, Mayer, F., additional, Reck, M., additional, Atanackovic, D., additional, Thomas, M., additional, Schneller, F., additional, Stoehlmacher, J., additional, Goekkurt, E., additional, Bernhard, H., additional, Groeschel, A., additional, Bals, R., additional, Schmidt, S., additional, Scheel, B., additional, Koch, S. D., additional, Lander, T., additional, Kallen, K., additional, and Knuth, A., additional

Published
2011
Full Text
View/download PDF

31. Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA.

Author

Kübler, H., primary, Maurer, T., additional, Stenzl, A., additional, Feyerabend, S., additional, Steiner, U., additional, Schostak, M., additional, Schultze-Seemann, W., additional, vom Dorp, F., additional, Pilla, L., additional, Viatali, G., additional, Hampel, C., additional, Wedel, S., additional, Trojan, L., additional, Hiller, K., additional, Sommerauer, M., additional, Jocham, D., additional, Scheel, B., additional, Lander, T., additional, Kallen, K., additional, and Miller, K., additional

Published
2011
Full Text
View/download PDF

32. SELECTED ORAL COMMUNICATION SESSION, SESSION 60: CHILDREN'S HEALTH Wednesday 6 July 2011 10:00 - 11:45

Author

Epelboin, S., primary, Devouche, E., additional, Pejoan, H., additional, Viot, G., additional, Apter Danon, G., additional, Olivennes, F., additional, Follow Up ART Network, A., additional, Pinborg, A., additional, Loft, A., additional, Noergaard, L., additional, Henningsen, A. A., additional, Rasmussen, S., additional, Nyboe Andersen, A., additional, Davies, M. J., additional, Moore, V. M., additional, Willson, K., additional, Van Essen, P., additional, Scott, H., additional, Priest, K., additional, Haan, E. A., additional, Chan, A., additional, Sazonova, A., additional, Kallen, K., additional, Thurin-Kjellberg, A., additional, Wennerholm, U. B., additional, Bergh, C., additional, Wunder, D., additional, Neurohr, E. M., additional, Faouzi, M., additional, Birkhauser, M., additional, Garcia Cabrera, M., additional, Zurit, M. J., additional, Sainz, J. A., additional, De la Hoz, E., additional, Caballero, V., additional, Garrido, R., additional, Guo, M., additional, Richardson, M., additional, and Macklon, N. S., additional

Published
2011
Full Text
View/download PDF

34. Posters * Safety & Quality (I.E. Guidelines, Multiple Pregnancy, Outcome, Follow-Up etc.)

Author

Ocal, P., primary, Sahmay, S., additional, Irez, T., additional, Senol, H., additional, Cepni, I., additional, Purisa, S., additional, Lin, W., additional, Liu, X., additional, Donjacour, A., additional, Maltepe, E., additional, Rinaudo, P., additional, Baumgarten, M. N., additional, Stoop, D., additional, Haentjes, P., additional, Verheyen, G., additional, De Schrijver, F., additional, Liebaers, I., additional, Camus, M., additional, Bonduelle, M., additional, Devroey, P., additional, Nelissen, E. C. M., additional, Van Montfoort, A. P. A., additional, Coonen, E., additional, Derhaag, J. G., additional, Evers, J. L. H., additional, Dumoulin, J. C. M., additional, Costa Lopes, J. R., additional, Mendes dos Santos, J., additional, Portugal Silva Lima, S., additional, Portugal Silva Souza, S., additional, Rodrigues Pereira, T., additional, Barguil Brasileiro, J. P., additional, Pina, H., additional, Lessa, M. L., additional, Genovese Soares, M., additional, Medina Lopes, V., additional, Ribeiro, C. G., additional, Adami, K., additional, Hughes, C., additional, Emerson, G., additional, Grundy, K., additional, Kelly, P., additional, Mocanu, E., additional, Coelho Cafe, T., additional, de Souza Costa, J. B. M., additional, Zavattiero Tierno, N. I., additional, Singh, S., additional, Vitthala, S., additional, Zosmer, A., additional, Sabatini, L., additional, Tozer, A., additional, Davis, C., additional, Al-Shawaf, T., additional, Neri, Q. V., additional, Monahan, D., additional, Rosenwaks, Z., additional, Palermo, G. D., additional, Kalu, E., additional, Thum, M. Y., additional, Abdalla, H. A., additional, Sazonova, A., additional, Bergh, C., additional, Kallen, K., additional, Thurin-Kjellberg, A., additional, Wennerholm, U. B., additional, Griesinger, G., additional, Doody, K., additional, Witjes, H., additional, Mannaerts, B., additional, Tarlatzis, B., additional, Rombauts, L., additional, Heijnen, E., additional, Marintcheva-Petrova, M., additional, Elbers, J., additional, Koning, A., additional, Mutsaerts, M. A. Q., additional, Hoek, A., additional, Mol, B. W., additional, Fadini, R., additional, Guarnieri, T., additional, Mignini Renzini, M., additional, Comi, R., additional, Mastrolilli, M., additional, Villa, A., additional, Colpi, E., additional, Coticchio, G., additional, Dal Canto, M., additional, Dolleman, M., additional, Broer, S. L., additional, Opmeer, B. C., additional, Fauser, B. C., additional, Broekmans, F. J. M., additional, Alama, P., additional, Requena, A., additional, Crespo, J., additional, Munoz, M., additional, Ballesteros, A., additional, Munoz, E., additional, Fernandez, M., additional, Meseguer, M., additional, Garcia-Velasco, J. A., additional, Pellicer, A., additional, Munk, M., additional, Smidt-Jensen, S., additional, Blaabjerg, J., additional, Christoffersen, C., additional, Lenz, S., additional, Lindenberg, S., additional, Bosch, E., additional, Labarta, E., additional, Cruz, F., additional, Simon, C., additional, Remohi, J., additional, Esler, J., additional, Osborn, J., additional, Boissonnas Chalas, C., additional, Marszalek, A., additional, Fauque, P., additional, Wolf, J. P., additional, De Ziegler, D., additional, Cabanes, L., additional, Jouannet, P., additional, Han, A. R., additional, Park, C. W., additional, Cha, S. W., additional, Kim, H. O., additional, Yang, K. M., additional, Kim, J. Y., additional, Song, I. O., additional, Koong, M. K., additional, Kang, I. S., additional, Roszaman, R., additional, Omar, M. H., additional, Nazri, Y., additional, Azantee, Y. W., additional, Murad, A. Z., additional, Zainulrashid, M. R., additional, Wang, N., additional, Le, F., additional, Wang, L. Y., additional, Ding, G. L., additional, Sheng, J. Z., additional, Huang, H. F., additional, Jin, F., additional, Reinblatt, S., additional, Holzer, H., additional, Son, W. Y., additional, Shalom-Paz, E., additional, Chian, R. C., additional, Buckett, W., additional, Dahan, M., additional, Demirtas, E., additional, Tan, S. L., additional, Revel, A., additional, Schejter-Dinur, Y., additional, Revel-Vilk, S., additional, Hermens, R. P. M. G., additional, van den Boogaard, E., additional, Leschot, N. J., additional, Vollebergh, J. H. A., additional, Bernardus, R., additional, Kremer, J. A. M., additional, van der Veen, F., additional, Goddijn, M., additional, Nahuis, M. J., additional, Kose, N., additional, Bayram, N., additional, Hompes, P. G. A., additional, Mol, B. W. J., additional, van der veen, F., additional, van Wely, M., additional, Van Disseldorp, J., additional, Dolleman, M. D., additional, Broeze, K., additional, De Rycke, M., additional, Petrussa, L., additional, Van de Velde, H., additional, Cerrillo, M., additional, Pacheco, A., additional, Rodriguez, S., additional, Gomez, R., additional, Delagado, F., additional, Garcia Velasco, J. A., additional, Desmyttere, S., additional, Verpoest, W., additional, Staessen, C., additional, De Vos, A., additional, Kohls, G., additional, Ruiz, F. J., additional, De la Fuente, G., additional, Toribio, M., additional, Martinez, M., additional, Soderstrom - Anttila, V., additional, Salevaara, M., additional, Suikkari, A. M., additional, Clua, E., additional, Tur, R., additional, Alcaniz, N., additional, Boada, M., additional, Rodriguez, I., additional, Barri, P. N., additional, Veiga, A., additional, Nelen, W. L. D. M., additional, Van Empel, I. W. H., additional, Cohlen, B. J., additional, Laven, J. S., additional, Aarts, J. W. M., additional, Ricciarelli, E., additional, Gomez-Palomares, J. L., additional, Andres-Criado, L., additional, Hernandez, E. R., additional, Courbiere, B., additional, Aye, M., additional, Perrin, J., additional, Di Giorgio, C., additional, De Meo, M., additional, Botta, A., additional, Castilla Alcala, J., additional, Luceno Maestre, F., additional, Cabello, Y., additional, Hernandez, J., additional, Marqueta, J., additional, Pareja, A., additional, Hernandez, E., additional, Coroleu, B., additional, Helmgaard, L., additional, Klein, B. M., additional, Arce, J. C., additional, van Empel, I. W. H., additional, Boivin, J., additional, Verhaak, C. M., additional, Ding, G., additional, Yin, R., additional, Sheng, J., additional, Huang, H., additional, Mancini, F., additional, Gomez, M. J., additional, van den Boogaard, N. M., additional, van der Steeg, J. W., additional, Hompes, P., additional, Boyer, P., additional, Gervoise-Boyer, M., additional, Meddeb, L., additional, Rossin, B., additional, Audibert, F., additional, Sakian, S., additional, Chan Wong, E., additional, Ma, S., additional, Pathak, R., additional, Mustafa, M. D., additional, Ahmed, R. S., additional, Tripathi, A. K., additional, Guleria, K., additional, Banerjee, B. D., additional, Vela, G., additional, Luna, M., additional, Flisser, E. D., additional, Sandler, B., additional, Brodman, M., additional, Grunfeld, L., additional, Copperman, A. B., additional, Baronio, M., additional, Carrascosa, P., additional, Capunay, C., additional, Vallejos, J., additional, Papier, S., additional, Borghi, M., additional, Sueldo, C., additional, Carrascosa, J., additional, Martin Lopez, E., additional, Marcucci, A., additional, Marcucci, I., additional, Salacone, P., additional, Sebastianelli, A., additional, Caponecchia, L., additional, Pacini, N., additional, Rago, R., additional, Alvarez, M., additional, Carreras, O., additional, Arnoldi, M., additional, Diaferia, D., additional, Corbucci, M. G., additional, De Lauretis, L., additional, Kook, M. J., additional, Jung, J. Y., additional, Lee, J. H., additional, Jung, Y. J., additional, Hwang, H. K., additional, Kang, A., additional, An, S. J., additional, Kim, H. M., additional, Kwon, H. C., additional, Lee, S. J., additional, Satoh, M., additional, Imada, J., additional, Ito, K., additional, Migishima, F., additional, Inoue, T., additional, Ohnishi, Y., additional, Kawato, H., additional, Nakaoka, Y., additional, Fukuda, A., additional, Morimoto, Y., additional, Mourad, S., additional, Grol, R. P. T. M., additional, Polyzos, N. P., additional, Valachis, A., additional, Patavoukas, E., additional, Papanikolaou, E. G., additional, Messinis, I. E., additional, Tarlatzis, B. C., additional, Kang, H., additional, Kim, C. H., additional, Park, E., additional, Kim, S., additional, Chae, H. D., additional, Kang, B. M., additional, Jung, K. S., additional, Song, H. J., additional, Ahn, Y. S., additional, Petkova, L., additional, Canov, I., additional, Milachich, T., additional, Shterev, A., additional, Patrat, C., additional, Pocate, K., additional, Juillard, J. C., additional, Gayet, V., additional, Blanchet, V., additional, de Ziegler, D., additional, van der, J. W., additional, Leushuis, E., additional, Steures, P., additional, Koks, C., additional, Oosterhuis, J., additional, Bourdrez, P., additional, and Bossuyt, P. M., additional

Published
2010
Full Text
View/download PDF

38. Improving the efficacy of cancer immunotherapy

Author

Copier, J., primary, Dalgleish, A.G., additional, Britten, C.M., additional, Finke, L.H., additional, Gaudernack, G., additional, Gnjatic, S., additional, Kallen, K., additional, Kiessling, R., additional, Schuessler-Lenz, M., additional, Singh, H., additional, Talmadge, J., additional, Zwierzina, H., additional, and Håkansson, L., additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results